UroGen Pharma Ltd - Asset Resilience Ratio
UroGen Pharma Ltd (URGN) has an Asset Resilience Ratio of 11.42% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See URGN working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2025)
This chart shows how UroGen Pharma Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see UroGen Pharma Ltd asset portfolio.
Liquid Assets Composition Over Time
This chart breaks down UroGen Pharma Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore UroGen Pharma Ltd (URGN) long-term investment share to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $28.84 Million | 11.42% |
| Total Liquid Assets | $28.84 Million | 11.42% |
Asset Resilience Insights
- Moderate Liquidity: UroGen Pharma Ltd has 11.42% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
UroGen Pharma Ltd Industry Peers by Asset Resilience Ratio
Compare UroGen Pharma Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for UroGen Pharma Ltd (2015–2025)
The table below shows the annual Asset Resilience Ratio data for UroGen Pharma Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 4.84% | $9.71 Million | $200.46 Million | -17.80pp |
| 2024-12-31 | 22.64% | $64.70 Million | $285.71 Million | -0.89pp |
| 2023-12-31 | 23.54% | $41.97 Million | $178.31 Million | -9.32pp |
| 2022-12-31 | 32.85% | $44.56 Million | $135.62 Million | -4.54pp |
| 2021-12-31 | 37.39% | $44.78 Million | $119.75 Million | -2.89pp |
| 2020-12-31 | 40.29% | $49.15 Million | $122.00 Million | -7.83pp |
| 2019-12-31 | 48.12% | $97.39 Million | $202.39 Million | +0.47pp |
| 2017-12-31 | 47.65% | $36.00 Million | $75.55 Million | +47.24pp |
| 2016-12-31 | 0.41% | $95.00K | $23.06 Million | +0.30pp |
| 2015-12-31 | 0.11% | $21.00K | $19.39 Million | -- |
About UroGen Pharma Ltd
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder… Read more